Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

gemopatrilat

Known as: (6S)-Hexahydro-6-((alphaS)-alpha-mercaptohydrocinnamamido)-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Azepines

Narrower (1)

BMS-189921

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
METABOLISM OF [14C]GEMOPATRILAT AFTER ORAL ADMINISTRATION TO RATS, DOGS, AND HUMANS
This study describes the pharmacokinetic parameters of gemopatrilat, a potent vasopeptidase inhibitor, in humans and the… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
2003
2003
Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes.
BACKGROUND Control of blood pressure (BP) and optimal reduction of proteinuria (Uprot) are necessary for long-term renoprotection… Expand
Review
2002
Review
2002
Vasopeptidase inhibitors.
  • G. Sagnella
  • Journal of the renin-angiotensin-aldosterone…
  • 2002
    • Corpus ID: 24479593
Vasopeptidase inhibitors are a new class of drugs that have dual inhibitory effects on two key enzymes involved in the metabolism… Expand
Review
2002
Review
2002
Review: Vasopeptidase inhibitors
Vasopeptidase inhibitors are a new class of drugs that have dual inhibitory effects on two key enzymes involved in the metabolism… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
2001
2001
In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat
Objectives Vasopeptidase inhibitors are single molecules that simultaneously inhibit neutral endopeptidase (NEP) and angiotensin… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE